Novartis AG
- Open
- —
- Day range
- CHF 126.76 – CHF 129.68
- 52-week range
- CHF 99.45 – CHF 137.00
- Volume
- 5.13M
- Market cap
- —
- P/E (TTM)
- —
Historical closes from the market data provider. Adjusted for splits; corporate actions can affect comparability across periods.
Valuation and quality metrics
Annual financial statements
Fiscal years 2022, 2023, 2024, 2025. All figures in CHF. Values are as reported by the company.
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total revenue | CHF 43.46B | CHF 46.66B | CHF 51.72B | CHF 56.67B |
| Gross profit | CHF 31.88B | CHF 34.19B | CHF 38.90B | CHF 42.98B |
| Operating income | CHF 7.95B | CHF 9.77B | CHF 14.54B | CHF 17.64B |
| Net income | CHF 6.96B | CHF 14.85B | CHF 11.94B | CHF 13.98B |
| Diluted EPS | 3.17 | 7.10 | 5.87 | 7.15 |
| Total assets | CHF 117.45B | CHF 99.95B | CHF 102.25B | CHF 110.95B |
| Shareholders' equity | CHF 59.34B | CHF 46.67B | CHF 44.05B | CHF 46.13B |
| Operating cash flow | CHF 14.24B | CHF 14.46B | CHF 17.62B | CHF 19.14B |
| Free cash flow | CHF 12.00B | CHF 11.71B | CHF 13.81B | CHF 15.24B |
Annual statements sourced from the market data provider. Companies with different fiscal year ends are not directly comparable on a calendar basis.
| Ex-date | Amount per share |
|---|---|
| 10 Mar 2026 | CHF 3.7000 |
| 11 Mar 2025 | CHF 3.5000 |
| 07 Mar 2024 | CHF 3.3000 |
| 09 Mar 2023 | CHF 3.2000 |
| 08 Mar 2022 | CHF 3.1000 |
Amounts are as declared and are not adjusted for withholding tax. Dividend policy can change at any time.